PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
Main Authors: | Lihua Qiu, Tingyu Wang, Xiuhua Sun, Hang Su, Junning Cao, Zhi-Ming LI, Yuqin Song, LI Zhang, Dengju LI, Huijing Wu, Wei Zhang, Junmin LI, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng LI, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, Fei LI, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun LI, Shuhua Yi, Lugui Qiu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000975820.37624.bc |
Similar Items
-
PB2269: PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
by: Xiuhua Sun, et al.
Published: (2023-08-01) -
2272
by: Tamika Zapolski, et al.
Published: (2017-09-01) -
P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL
by: T. wang, et al.
Published: (2022-06-01) -
P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY
by: LI Zhi-Ming, et al.
Published: (2023-08-01) -
Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats
by: Carlos Arturo Levi D’Ancona, et al.
Published: (2010-12-01)